Analytical Quality Control News

OTC Drug Production Ceased after FDA Warning Letter

The U.S. Food and Drug Administration (FDA) has issued a new Warning Letter following an inspection that uncovered serious GMP deficiencies in the manufacturing of an OTC drug product, including missing release testing, lack of stability data, and inadequate quality oversight.

More
EMA publishes four new product-specific Bioequivalence Guidance

The European Medicines Agency (EMA) has published the finalised product-specific bioequivalence guidelines for Budesonide and Tolvaptan. The documents will come into effect on 1 September 2025.

More
Pharmeuropa: New Chapter on Evaporative Light-Scattering Detection published for Comment

The Pharmeuropa issue 37.2 includes a draft for a new chapter 2.2.62, Evaporative Light-Scattering Detection. Comments on the draft can be submitted until 30 June 2025.

More
FDA Warning Letter: Missing Ongoing Stability Program for Biotech APIs

In March 2025, the U.S. FDA issued a Warning Letter (WL) to the Indian company "Aspen Biopharma Labs Private Limited" after having inspected its site in September 2024 and criticised the company's stability program.

More
Pharmeuropa: Four Draft Chapters on Elemental Analysis Published for Comment

In the Pharmeuropa issue 37.2, four draft chapters on elemental analysis methods were published for public comment: 2.2.22. Atomic emission spectrometry, 2.2.23. Atomic absorption spectrometry, 2.2.57. Inductively coupled plasma-atomic emission spectrometry, and 2.2.58. Inductively coupled plasma-mass spectrometry.

More
Missing Tests and Altered Records: FDA Warns Chinese OTC Manufacturer

A recent FDA Warning Letter to a Chinese OTC manufacturer highlights serious deficiencies in analytical testing, inadequate quality oversight, and multiple data integrity issues. These include missing data, discrepancies between original and re-written testing records and certificates of analysis (COAs), and the use of correction fluid (white-out) to alter laboratory documentation.

More
Become a speaker at PharmaLab 2025 - Analytics, Bioanalytics, Microbiology and more

The 13th PharmaLab Congress from November 24-28, 2025 will take place as usual in Neuss/Düsseldorf with two pre-conference workshops and several parallel conferences. As always, it offers you the opportunity to become part of the speaker team and submit a presentation to share your knowledge with colleagues and discuss the respective experiences. So, become part of the team of speakers - and submit your proposal for a presentation via our online form.

More
Inadequate Dissolution Testing and Process Validation Trigger FDA Warning Letter

The U.S. Food and Drug Administration (FDA) has issued a new Warning Letter due to CGMP violations related to combination products. Key violations include inadequate controls to ensure the sterility of drug products, deficient dissolution testing, and a lack of process validation.

More
WHO: Update of Guideline of Reference Standards

The WHO recently published the “Working document QAS/25.972” of the “WHO General guidelines for the establishment, maintenance and distribution of chemical reference substances” on the subject of reference standards on its website for comments. The comment period is scheduled to last until May 7, 2025.

More
FDA issues Warning Letter due to GMP Violations at Chinese Drug Manufacturer

The United States Food and Drug Administration has issued a Warning Letter to a Chinese manufacturer. The violations include inadequate raw material testing and insufficient stability testing programs.

More
x
Search